ZA200608693B - MAGE-3 and NY-ESO-1 based polyvalent vaccine for cancer immunotherapy - Google Patents

MAGE-3 and NY-ESO-1 based polyvalent vaccine for cancer immunotherapy

Info

Publication number
ZA200608693B
ZA200608693B ZA200608693A ZA200608693A ZA200608693B ZA 200608693 B ZA200608693 B ZA 200608693B ZA 200608693 A ZA200608693 A ZA 200608693A ZA 200608693 A ZA200608693 A ZA 200608693A ZA 200608693 B ZA200608693 B ZA 200608693B
Authority
ZA
South Africa
Prior art keywords
eso
mage
cancer immunotherapy
polyvalent vaccine
based polyvalent
Prior art date
Application number
ZA200608693A
Other languages
English (en)
Inventor
Claudine Elvire Marie Bruck
Remi M Plamantier
Vincent Brichardt
Melinda Meaders
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of ZA200608693B publication Critical patent/ZA200608693B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001188—NY-ESO
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
ZA200608693A 2004-05-04 2006-10-18 MAGE-3 and NY-ESO-1 based polyvalent vaccine for cancer immunotherapy ZA200608693B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0409940.4A GB0409940D0 (en) 2004-05-04 2004-05-04 Vaccine

Publications (1)

Publication Number Publication Date
ZA200608693B true ZA200608693B (en) 2010-01-27

Family

ID=32482653

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200608693A ZA200608693B (en) 2004-05-04 2006-10-18 MAGE-3 and NY-ESO-1 based polyvalent vaccine for cancer immunotherapy

Country Status (16)

Country Link
US (1) US20070243196A1 (xx)
EP (1) EP1755657A2 (xx)
JP (1) JP2007536326A (xx)
CN (1) CN1980691A (xx)
AU (1) AU2005237256A1 (xx)
BR (1) BRPI0510570A (xx)
CA (1) CA2564470A1 (xx)
GB (1) GB0409940D0 (xx)
IL (1) IL178681A0 (xx)
MA (1) MA28639B1 (xx)
MX (1) MXPA06012723A (xx)
NO (1) NO20065480L (xx)
NZ (1) NZ550967A (xx)
RU (1) RU2006138283A (xx)
WO (1) WO2005105139A2 (xx)
ZA (1) ZA200608693B (xx)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007137986A2 (en) * 2006-05-26 2007-12-06 Glaxosmithkline Biologicals Sa Vaccination against cancer
GB0612342D0 (en) * 2006-06-21 2006-08-02 Glaxosmithkline Biolog Sa Method
EP2118128B1 (en) * 2007-01-15 2012-11-07 GlaxoSmithKline Biologicals SA Fusion proteins comprising the tumor rejection antigens ny-eso-1 and lage-1
EP2125888B1 (en) 2007-03-13 2015-12-02 University of Zurich Method of providing human tumor-specific antibodies
AR066676A1 (es) 2007-05-24 2009-09-02 Glaxosmithkline Biolog Sa Composicion antigenica liofilizada que contiene un agonista del receptor tipo toll
WO2009127666A2 (en) * 2008-04-15 2009-10-22 Glaxosmithkline Biologicals S.A. Method and compositions
CN101381402B (zh) * 2008-10-20 2011-06-01 中国人民解放军第三军医大学 Ny-eso-1肿瘤抗原模拟表位及其应用
US20120039993A1 (en) 2009-03-17 2012-02-16 Glaxosmithkline Biologicals Sa Detection of Gene Expression
GB0910046D0 (en) 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
ES2617983T3 (es) * 2011-01-10 2017-06-20 Ct Atlantic Ltd. Terapia de combinación que incluye anticuerpos de unión a antígenos asociados a tumores
GB201116248D0 (en) 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
PL3542819T3 (pl) * 2013-05-14 2022-01-10 Zoetis Services Llc Nowe kompozycje szczepionek zawierających oligonukleotydy immunostymulujące
JP6697384B2 (ja) 2013-07-25 2020-05-20 イグジキュア, インコーポレーテッドExicure, Inc. 予防的および治療的使用のための免疫刺激剤としての球状の核酸ベース構築物
ES2725948T3 (es) 2014-06-04 2019-09-30 Exicure Inc Suministro multivalente de inmunomoduladores mediante ácidos nucleicos esféricos liposomales para aplicaciones profilácticas o terapéuticas
GB201413665D0 (en) 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
WO2016019298A2 (en) * 2014-08-01 2016-02-04 Texas Tech University System Cancer testis antigen sperm protein 17 as a target for breast cancer immunotherapy and diagnosis
US11213593B2 (en) 2014-11-21 2022-01-04 Northwestern University Sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
US11696954B2 (en) 2017-04-28 2023-07-11 Exicure Operating Company Synthesis of spherical nucleic acids using lipophilic moieties
WO2018226931A1 (en) * 2017-06-07 2018-12-13 David Weiner Mage-a vaccines and methods of treatment using the same
WO2019061297A1 (zh) * 2017-09-29 2019-04-04 苏州工业园区唯可达生物科技有限公司 一种cd4辅助性t细胞表位融合肽及其疫苗
GB201804468D0 (en) * 2018-03-21 2018-05-02 Valo Therapeutics Oy PeptiCRAd Cancer Therapy

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5278302A (en) * 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) * 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
FR2649013B1 (fr) * 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
FR2649012B1 (fr) * 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
EP0882246A1 (en) * 1996-02-23 1998-12-09 BRITISH TELECOMMUNICATIONS public limited company Optical interconnect
DE69943359D1 (de) * 1998-02-05 2011-05-26 Glaxosmithkline Biolog Sa Tumorassoziierte Antigenderivate der Mage-Familie, zur Herstellung von Fusionsproteinen mit T-Helper Epitope und Zusammensetzungen zur Impfung
US6686147B1 (en) * 1998-07-15 2004-02-03 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
US20030044813A1 (en) * 2001-03-30 2003-03-06 Old Lloyd J. Cancer-testis antigens

Also Published As

Publication number Publication date
IL178681A0 (en) 2007-02-11
JP2007536326A (ja) 2007-12-13
GB0409940D0 (en) 2004-06-09
NZ550967A (en) 2009-01-31
CA2564470A1 (en) 2005-11-10
BRPI0510570A (pt) 2007-11-20
MXPA06012723A (es) 2007-02-14
EP1755657A2 (en) 2007-02-28
US20070243196A1 (en) 2007-10-18
AU2005237256A1 (en) 2005-11-10
NO20065480L (no) 2006-11-28
MA28639B1 (fr) 2007-06-01
WO2005105139A3 (en) 2006-04-13
WO2005105139A2 (en) 2005-11-10
RU2006138283A (ru) 2008-06-10
CN1980691A (zh) 2007-06-13

Similar Documents

Publication Publication Date Title
ZA200608693B (en) MAGE-3 and NY-ESO-1 based polyvalent vaccine for cancer immunotherapy
TWI365191B (en) Vaccine
EP1874342A4 (en) COMPOSITIONS AND METHODS FOR CANCER IMMUNOTHERAPY
IL178890A0 (en) Vaccines
GB2434367B (en) Improved vaccines
EP1804831A4 (en) VACCINES BASED ON LLO AND LISTERIA
EP1827489A4 (en) USE OF FLAGELLIN FOR TUMORIMMUN THERAPY
EP1804583A4 (en) ADJUVANT FOR DNA VACCINE
EP1755665A4 (en) COMPOSITIONS AND METHODS FOR MUCOSAL VACCINATION
EP1768688A4 (en) ORAL BORRELIOSE VACCINE
EP1941278A4 (en) OPTIMAL POLYVALENT VACCINE FOR CANCER
EP1814393A4 (en) TOLEROGENIC VACCINE AND METHOD THEREOF
HK1214534A1 (zh) 流感疫苗
GB0420634D0 (en) Vaccines
EP1718330A4 (en) COMPLEX POLYPEPTIDE AND ADJUVANT FOR ENHANCED VACCINES
EP1871166A4 (en) VACCINES AGAINST CANCER AND THERAPEUTIC METHODS
GB0411150D0 (en) Vaccine
AP2695A (en) Vaccine adjuvants
GB0401876D0 (en) New use for cancer antigen
EP1757680A4 (en) ADOPTIVE IMMUNZELLE FOR TUMORIMPFSTOFF AND THE SAME
GB0413510D0 (en) Vaccine
EP2061506A4 (en) VACCINE COMPOSITION AND IMMUNIZATION METHOD
GB0428381D0 (en) Vaccine
GB0412407D0 (en) Vaccine
GB0419918D0 (en) Vaccine